KAMAL ADEELA enters ACTINIUM PHARMACEUTICALS, INC. with 213.65K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 9/10/2026ACC: 0001213900-26-098841
Officer· Chief Scientific Officer
Since Sep 2026
213.65K
Baseline shares
100% direct
213.65K
Direct ownership
1 position
120K
Derivative underlying
1 instrument
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned213.65K
Total
213.65K direct213.65K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 213.65K | Direct |
| Total | 213.65K | 213.65K direct |
Derivative Holdings1
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
120K
Shares owned
N/A
Exercise price
1.00
Expiration
—
Exercise window
—
Total
Underlying
120K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 1.00 | — | — | 120K | N/A |
| Total | 120K | 0.00 | ||||